Saint Joseph's Hospital/Children's Hospital-Tampa

Summary

Saint Joseph's Hospital/Children's Hospital-Tampa is a medical facility located in Tampa, Florida. This center is recognized for care of Cancer, Brain Tumor, Solid Tumors, Acute Lymphoblastic Leukemia, Neuroblastoma and other specialties. Saint Joseph's Hospital/Children's Hospital-Tampa is involved with conducting 193 clinical trials across 350 conditions. There are 12 research doctors associated with this hospital, such as Don Eslin, MD, Vijaya K. Gadiyaram, Roberto Diaz, and Ronica H. Nanda.

Top PIs

Clinical Trials running at Saint Joseph's Hospital/Children's Hospital-Tampa

Breast Cancer

Breast cancer

Brain Tumor

Lung Cancer

Cancer

Testicular cancer

Acute Lymphoblastic Leukemia

Colorectal Cancer

Leukemia

Melanoma

Omitting Radiation Therapy

for Breast Cancer

The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.

Recruiting

2 awards

Phase 3

19 criteria

Shorter Chemo-Immunotherapy Without Anthracyclines

for Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.

Recruiting

2 awards

Phase 3

47 criteria

HER2-Targeted Therapy

for Breast Cancer

This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complete response (pCR) after preoperative (neoadjuvant) chemotherapy with trastuzumab. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to a receptor protein called HER2. HER2 is found on some cancer cells. When trastuzumab or pertuzumab attach to HER2, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving 6 months of HER2-targeted therapy may work better than giving 12 months for the treatment of HER2+ breast cancer in patients that had a pCR after neoadjuvant chemotherapy with trastuzumab.

Recruiting

2 awards

Phase 3

5 criteria